EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?

Marica Cariello, Simon Ducheix, Salwan Maqdasy, Silvère Baron, Antonio Moschetta, Jean-Marc A Lobaccaro

Nuclear Receptor Signaling · 2018

DOI: 10.1177/1550762918801070 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nuclear Receptor Signaling, 2018. Verfasst von Marica Cariello und 5 weiteren Autor:innen. Beteiligte Einrichtung: "Aldo Moro" University of Bari, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Androgens and androgen receptor (AR, NR3C4) clearly play a crucial role in prostate cancer progression. Besides, the link between metabolic disorders and the risk of developing a prostate cancer has been emerging these last years. Interestingly, “lipid” nuclear receptors such as LXRα/NR1H3 and LXRβ/NR1H2 (as well as FXRα/NR1H4 and SHP/NR0B2) have been described to decrease the lipid metabolism, while AR increases it. Moreover, these former orphan nuclear receptors can regulate androgen levels and modulate AR activity. Thus, it is not surprising to find such receptors involved in the physiology of prostate. This review is focused on the roles of liver X receptors (LXRs), farnesoid X receptor (FXR), and small heterodimeric partner (SHP) in prostate physiology and their capabilities to interfere with the androgen-regulated pathways by modulating the levels of active androgen within the prostate. By the use of prostate cancer cell lines, mice deficient for these nuclear receptors and human tissue libraries, several authors have pointed out the putative possibility to pharmacologically target these receptors. These data open a new field of research for the development of new drugs that could overcome the castration resistance in prostate cancer, a usual phenomenon in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsHumansLiver X ReceptorsMaleProstatic NeoplasmsReceptors, AndrogenReceptors, Cytoplasmic and NuclearReceptor, Farnesoid X-Activated

Stichwörter der Autor:innen

FXRLXRSHPlipid metabolismprostate cancer

Substanzen

Liver X ReceptorsReceptors, AndrogenReceptors, Cytoplasmic and NuclearReceptor, Farnesoid X-Activatednuclear receptor subfamily 0, group B, member 2

Autor:innen und Institutionen

  • "Aldo Moro" University of Bari, Italy.
  • Istituto Nazionale Biostrutture e Biosistemi, Roma, Italy.
  • Université Clermont Auvergne, Clermont-Ferrand, France.
  • Centre de Recherche en Nutrition Humaine d'Auvergne, Clermont-Ferrand, France.
  • CHU Clermont-Ferrand, France.
  • IRCCS Istituto Oncologico "Giovanni Paolo II," Bari, Italy.

Zitieren

APA

Cariello, M., Ducheix, S., Maqdasy, S., Baron, S., Moschetta, A., & Lobaccaro, J. A. (2018). LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?. Nuclear Receptor Signaling. https://doi.org/10.1177/1550762918801070

Vancouver

Cariello M, Ducheix S, Maqdasy S, Baron S, Moschetta A, Lobaccaro JA. LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?. Nuclear Receptor Signaling. 2018. doi:10.1177/1550762918801070

BibTeX
@article{Cariello2018,
  author = {Cariello, Marica and Ducheix, Simon and Maqdasy, Salwan and Baron, Silvère and Moschetta, Antonio and Lobaccaro, Jean-Marc A},
  title = {LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?},
  journal = {Nuclear Receptor Signaling},
  year = {2018},
  doi = {10.1177/1550762918801070}
}
Kostenlos starten →